Insider · CIK 0001752059
Andrew T. Kaplan
Files at SGRY (Surgery Partners, Inc.), KLRA (Kailera Therapeutics, Inc.). First filing Dec 21, 2023, latest Apr 20, 2026.
In brief
Andrew T. Kaplan files SEC Form 4 as director and 10% owner at SGRY (Surgery Partners, Inc.), and also at KLRA (Kailera Therapeutics, Inc.). Since Dec 21, 2023, Andrew T. Kaplan has reported 1 open-market buy worth $134M and 1 open-market sell worth $262M, the latest filed on Apr 20, 2026.
A track record needs three past buys with six months of prices behind them; Andrew T. Kaplan has 0, so none is measured yet.
The newest scored trade: bought $134M of KLRA on Apr 20, 2026, filed Apr 20, 2026, scored 71 (notable). In the last 12 months: 1 buy worth $134M and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
KLRA: Kailera Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
SGRY: Surgery Partners, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 71Notable | Kailera Therapeutics, Inc. | $134M 8,398,438 shares | +47% | 0% from low-5% from high | |
| 60Notable | Surgery Partners, Inc. | $262M 7,826,870 shares | -13% | +46% from low-28% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +17,857,143 | - | - | 17,857,143 | Apr 20, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +8,398,438 | $16.00 | $134M | 26,255,581 | Apr 20, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -17,857,143 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Dec 19, 2023 | SGRY Surgery Partners, Inc. | SOpen-market sale Common Stockindirect: See footnote | -7,826,870 | $33.44 | $262M | 50,421,379 | Dec 21, 2023 |
| Dec 19, 2023 | SGRY Surgery Partners, Inc. | JOther Common Stockindirect: See footnote | -474,407 | $0.00 | $0 | 49,946,972 | Dec 21, 2023 |
Questions about Andrew T. Kaplan
Answered from the filings on this page, as of the latest one.
Is Andrew T. Kaplan buying or selling?
In the last 12 months Andrew T. Kaplan reported 1 open-market buy worth $134M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $134M of KLRA on Apr 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Andrew T. Kaplan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew T. Kaplan has 0.
Where does Andrew T. Kaplan file Form 4?
Andrew T. Kaplan has filed Form 4 at SGRY (Surgery Partners, Inc.); KLRA (Kailera Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.